Parkin overexpression ameliorates hippocampal long-term potentiation and β-amyloid load in an Alzheimer's disease mouse model

Human Molecular Genetics

Volumn 23, Issue 4, 2014, Pages 1056-1072

  Hong, Xiaoqi ^a   Liu, Jie ^a   Zhu, Guoqi ^a   Zhuang, YingHan ^a   Suo, Haiyun ^a   Wang, Pan ^a   Huang, Dongping ^a   Xu, Jing ^a   Huang, Yufang ^a   Yu, Mei ^a   Bian, MinJuan ^a   Sheng, Zhejin ^b   Fei, Jian ^b,c   Song, Houyan ^a   Behnisch, Thomas ^a   Huang, Fang ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c Shanghai Research Center for Model Organisms   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PARKIN; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; LOCOMOTION; LONG TERM POTENTIATION; MEMORY; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SYNAPTOPHYSIN; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84892982159     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt501     Document Type: Article

References (75)

1. Querfurth, H.W. and LaFerla, F.M. (2010) Alzheimer's disease. N. Engl. J. Med., 362, 329-344.
2. Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Burggren, A.C., Cole, G.M., Vinters, H.V. et al. (2006) PET Of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med., 355, 2652-2663.
3. Keller, J.N., Hanni, K.B. and Markesbery, W.R. (2000) Impaired proteasome function in Alzheimer's disease. J. Neurochem., 75, 436-439.
4. de Vrij, F.M., Fischer, D.F., van Leeuwen, F.W. and Hol, E.M. (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol., 74, 249-270.
5. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
6. Venderova, K., Kabbach, G., Abdel-Messih, E., Zhang, Y., Parks, R.J., Imai, Y., Gehrke, S., Ngsee, J., Lavoie, M.J., Slack, R.S. et al. (2009) Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet., 18, 4390- 4404.
7. Lu, X.H., Fleming, S.M., Meurers, B., Ackerson, L.C., Mortazavi, F., Lo, V., Hernandez, D., Sulzer, D., Jackson, G.R., Maidment, N.T. et al. (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J. Neurosci., 29, 1962-1976.
8. Rodriguez-Navarro, J.A., Gomez, A., Rodal, I., Perucho, J., Martinez, A., Furio, V., Ampuero, I., Casarejos, M.J., Solano, R.M., de Yebenes, J.G. et al. (2008) Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice. Hum. Mol. Genet., 17, 3128-3143.
9. Nemes, Z., Devreese, B., Steinert, P.M., Van Beeumen, J. and Fesus, L. (2004) Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J., 18, 1135-1137.
10. Menendez, J., Rodriguez-Navarro, J.A., Solano, R.M., Casarejos, M.J., Rodal, I., Guerrero, R., Sanchez, M.P., Avila, J., Mena, M.A. and de Yebenes, J.G. (2006) Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein. Hum. Mol. Genet., 15, 2045-2058.
11. Guerrero, R., Navarro, P., Gallego, E., Garcia-Cabrero, A.M., Avila, J. and Sanchez, M.P. (2009) Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene. Acta Neuropathol., 117, 159-168.
12. Kim, K.Y. and Sack, M.N. (2012) Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease. Curr. Opin. Lipidol., 23, 201-205.
13. Abumrad, N.A. and Moore, D.J. (2011) Parkin reinvents itself to regulate fatty acid metabolism by tagging CD36. J. Clin. Invest., 121, 3389-3392.
14. Rosen, K.M., Veereshwarayya, V., Moussa, C.E., Fu, Q., Goldberg, M.S., Schlossmacher, M.G., Shen, J. and Querfurth, H.W. (2006) Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J. Biol. Chem., 281, 12809-12816.
15. Rosen, K.M., Moussa, C.E., Lee, H.K., Kumar, P., Kitada, T., Qin, G., Fu, Q. and Querfurth, H.W. (2010) Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J. Neurosci. Res., 88, 167-178.
16. Khandelwal, P.J., Herman, A.M., Hoe, H.S., Rebeck, G.W. and Moussa, C.E. (2011) Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum. Mol. Genet., 20, 2091-2102.
17. Burns, M.P., Zhang, L., Rebeck, G.W., Querfurth, H.W. and Moussa, C.E. (2009) Parkin promotes intracellular Abeta1-42 clearance. Hum. Mol. Genet., 18, 3206-3216.
18. Bian, M., Liu, J., Hong, X., Yu, M., Huang, Y., Sheng, Z., Fei, J. and Huang, F. (2012) Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS One, 7, e39953.
19. Filali, M., Lalonde, R. and Rivest, S. (2009) Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav., 8, 143-148.
20. Garcia-Alloza, M., Robbins, E.M., Zhang-Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., Prada, C., Greenberg, S.M., Bacskai, B.J. and Frosch, M.P. (2006) Characterization of amyloid deposition in the APPswe/ PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis., 24, 516-524.
21. Jankowsky, J.L., Slunt, H.H., Ratovitski, T., Jenkins, N.A., Copeland, N.G. and Borchelt, D.R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng., 17, 157-165.
22. Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A., Copeland, N.G., Lee, M.K., Younkin, L.H., Wagner, S.L. et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet., 13, 159-170.
23. Reiserer, R.S., Harrison, F.E., Syverud, D.C. and McDonald, M.P. (2007) Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav., 6, 54-65.
24. Lalonde, R., Kim, H.D., Maxwell, J.A. and Fukuchi, K. (2005) Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/ DeltaE9 mice with amyloid plaques. Neurosci. Lett., 390, 87-92.
25. Morris, R.G., Garrud, P., Rawlins, J.N. and O'Keefe, J. (1982) Place navigation impaired in rats with hippocampal lesions. Nature, 297, 681-683.
26. Tsien, J.Z., Huerta, P.T. and Tonegawa, S. (1996) The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell, 87, 1327-1338.
27. Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P.M. and Arancio, O. (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol., 55, 801-814.
28. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y. and LaFerla, F.M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A beta and synaptic dysfunction. Neuron, 39, 409-421.
29. Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H. and Younkin, S.G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci., 21, 372-381.
30. Borchelt, D.R., Ratovitski, T., van Lare, J., Lee, M.K., Gonzales, V., Jenkins, N.A., Copeland, N.G., Price, D.L. and Sisodia, S.S. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron, 19, 939-945.
31. Ehlers, M.D. (2003) Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat. Neurosci., 6, 231-242.
32. Cai, F., Frey, J.U., Sanna, P.P. and Behnisch, T. (2010) Protein degradation by the proteasome is required for synaptic tagging and the heterosynaptic stabilization of hippocampal late-phase long-term potentiation. Neuroscience, 169, 1520-1526.
33. Karpova, A., Mikhaylova, M., Thomas, U., Knopfel, T. and Behnisch, T. (2006) Involvement of protein synthesis and degradation in long-term potentiation of Schaffer collateral CA1 synapses. J. Neurosci., 26, 4949-4955.
34. Perry, G., Friedman, R., Shaw, G. and Chau, V. (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl Acad. Sci. USA, 84, 3033-3036.
35. Oddo, S. (2008) The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med., 12, 363-373.
36. Choi, J., Levey, A.I., Weintraub, S.T., Rees, H.D., Gearing, M., Chin, L.S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem., 279, 13256-13264.
37. Gong, B., Cao, Z., Zheng, P., Vitolo, O.V., Liu, S., Staniszewski, A., Moolman, D., Zhang, H., Shelanski, M. and Arancio, O. (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell, 126, 775-788.
38. Flood, F., Murphy, S., Cowburn, R.F., Lannfelt, L., Walker, B. and Johnston, J.A. (2005) Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. Biochem. J., 385, 545-550.
39. Nunan, J., Shearman, M.S., Checler, F., Cappai, R., Evin, G., Beyreuther, K., Masters, C.L. and Small, D.H. (2001) The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur. J. Biochem., 268, 5329-5336.
40. Um, J.W., Im, E., Lee, H.J., Min, B., Yoo, L., Yoo, J., Lubbert, H., Stichel-Gunkel, C., Cho, H.S., Yoon, J.B. et al. (2010) Parkin directly modulates 26S proteasome activity. J. Neurosci., 30, 11805-11814.
41. Moussa, C.E. (2009) Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein. J. Mol. Neurosci., 37, 25-36.
42. Ruan, L., Kang, Z., Pei, G. and Le, Y. (2009) Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr. Alzheimer Res., 6, 531-540.
43. Beal, M.F. (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci., 991, 120-131.
44. Andersen, J.K. (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat. Med., 10(Suppl), S18-S25.
45. Palacino, J.J., Sagi, D., Goldberg, M.S., Krauss, S., Motz, C., Wacker, M., Klose, J. and Shen, J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 279, 18614-18622.
46. Greene, J.C., Whitworth, A.J., Kuo, I., Andrews, L.A., Feany, M.B. and Pallanck, L.J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U. S. A., 100, 4078-4083.
47. Rebeck, G.W., Hoe, H.S. and Moussa, C.E. (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J. Biol. Chem., 285, 7440-7446.
48. Bliss, T.V. and Collingridge, G.L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31-39.
49. Tse, D., Takeuchi, T., Kakeyama, M., Kajii, Y., Okuno, H., Tohyama, C., Bito, H. and Morris, R.G. (2011) Schema-dependent gene activation and memory encoding in neocortex. Science, 333, 891-895.
50. Ronicke, R., Mikhaylova, M., Ronicke, S., Meinhardt, J., Schroder, U.H., Fandrich, M., Reiser, G., Kreutz, M.R. and Reymann, K.G. (2011) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging, 32, 2219-2228.
51. Nussbaum, J.M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Ronicke, R. et al. (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature, 485, 651-655.
52. Klyubin, I., Cullen, W.K., Hu, N.W. and Rowan, M.J. (2012) Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol. Brain, 5, 25.
53. Klyubin, I., Walsh, D.M., Lemere, C.A., Cullen, W.K., Shankar, G.M., Betts, V., Spooner, E.T., Jiang, L., Anwyl, R., Selkoe, D.J. et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med., 11, 556-561.
54. Hauss-Wegrzyniak, B., Lynch, M.A., Vraniak, P.D. and Wenk, G.L. (2002) Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp. Neurol., 176, 336-341.
55. Liu, H.L., Zhao, G., Cai, K., Zhao, H.H. and Shi, L.D. (2011) Treadmill exercise prevents decline in spatial learning and memory in APP/PS1 transgenic mice through improvement of hippocampal long-term potentiation. Behav. Brain Res., 218, 308-314.
56. Reisberg, B., Borenstein, J., Salob, S.P., Ferris, S.H., Franssen, E. and Georgotas, A. (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry, 48(Suppl), 9-15.
57. Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D. and Parnetti, L. (2006) Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev., 127, 158-165.
58. Harrison, F.E., Hosseini, A.H. and McDonald, M.P. (2009) Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav. Brain Res., 198, 247-251.
59. Rana, A., Rera, M. and Walker, D.W. (2013) Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc. Natl Acad. Sci. USA, 110, 8638-8643.
60. Chen, Y. and Dorn, G.W. II (2013) PINK1-phosphorylated Mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science, 340, 471-475.
61. Sarraf, S.A., Raman, M., Guarani-Pereira, V., Sowa, M.E., Huttlin, E.L., Gygi, S.P. and Harper, J.W. (2013) Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature, 496, 372-376.
62. Bian, M., Yu, M., Yang, S., Gao, H., Huang, Y., Deng, C., Gao, Y., Sun, F. and Huang, F. (2008) Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenylpyridinium ion-treated dopaminergic SH-SY5Y cells. Acta Biochim. Biophys. Sin. (Shanghai), 40, 505-512.
63. Devi, L., Alldred, M.J., Ginsberg, S.D. and Ohno, M. (2010) Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol. Brain, 3, 34.
64. Wilcock, D.M., Gordon, M.N. and Morgan, D. (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc., 1, 1591-1595.
65. Yu, M., Suo, H., Liu, M., Cai, L., Liu, J., Huang, Y., Xu, J., Wang,Y., Zhu, C., Fei, J. et al. (2012)NRSF/RESTneuronal deficient mice are more vulnerable to the neurotoxin MPTP. Neurobiol. Aging, 34, 916-927.
66. Lopez-Salon, M., Alonso, M., Vianna, M.R., Viola, H., Mello e Souza, T., Izquierdo, I., Pasquini, J.M. and Medina, J.H. (2001) The ubiquitinproteasome cascade is required for mammalian long-term memory formation. Eur. J. Neurosci., 14, 1820-1826.
67. Hunter, R.L., Cheng, B., Choi, D.Y., Liu, M., Liu, S., Cass, W.A. and Bing, G. (2009) Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J. Neurosci. Res., 87, 1913-1921.
68. Zhu, G., Chen, Y., Huang, Y., Li, Q. and Behnisch, T. (2011) MPTP-meditated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity. Toxicol. Appl. Pharmacol., 254, 332-341.
69. Chen, Y., Yuanxiang, P., Knopfel, T., Thomas, U. and Behnisch, T. (2012) HippocampalLTPtriggers proteasome-mediatedSPARdegradation inCA1 neurons. Synapse, 66, 142-150.
70. Behnisch, T., Yuanxiang, P., Bethge, P., Parvez, S., Chen, Y., Yu, J., Karpova, A., Frey, J.U., Mikhaylova, M. and Kreutz, M.R. (2011) Nuclear translocation of Jacob in hippocampal neurons after stimuli inducing long-term potentiation but not long-term depression. PLoS One, 6, e17276.
71. Prut, L. and Belzung, C. (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol., 463, 3-33.
72. Kalueff, A.V. and Tuohimaa, P. (2004) Experimental modeling of anxiety and depression. Acta Neurobiol. Exp. (Wars), 64, 439-448.
73. Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B.P., Maldonado, R. and Kieffer, B.L. (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J., 17, 886-897.
74. Vorhees, C.V. and Williams, M.T. (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc., 1, 848-858.
75. Morris, R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods, 11, 47-60.